Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Lung Cancer (NSCLC): early-phase trial registry

8 of 8 indexed Lung Cancer (NSCLC) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 8 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Lung Cancer (NSCLC): 8 US clinical trials tracked, 8 recruiting.

Lung Cancer (NSCLC) is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Ballad Health, running 1 of these trials.

Enrollment posture brief

Registry condition lung-cancer-nsclc

OPEN 8 | RECR 100% | LATE 0 | EARLY 5 | RANK #2176 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Lung Cancer (this)100%Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Lung Cancer (NSCLC)

Lung Cancer (NSCLC) lists 8 open slots (100% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer (NSCLC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer (NSCLC) is recruiting above its size-band peers.

    8 of 8 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Cancer (NSCLC) trials is spread across many organizations.

    Ballad Health accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Cancer (NSCLC) enrolment sits around 194 participants.

    Median target enrolment is 194 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.

  4. Lung Cancer (NSCLC) research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Named interventions

Most-linked intervention names on Lung Cancer (NSCLC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Circulogene liquid biopsy testing Diagnostic test
1 trials
PHN-012 Drug
1 trials
Lay Health Worker (LHW) Planning Behavioral
1 trials
JBI-802 Drug
1 trials
Practical Geriatric Assessment Other
1 trials
Usual Care Group Other
1 trials
TJ101 Drug
1 trials
Pembrolizumab (KEYTRUDA®) Drug
1 trials

US sites by state

Facility locations filed on Lung Cancer (NSCLC) trials. A trial with sites in several states counts in each.

Texas 4 trials
Tennessee 4 trials
Virginia 2 trials
Ohio 2 trials
Michigan 2 trials
Massachusetts 2 trials
Florida 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Cancer (NSCLC) page

8 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 8 Lung Cancer (NSCLC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Ballad Health sponsors the most Lung Cancer (NSCLC) trials on record, review their full trial history before evaluating a specific study. See Ballad Health's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer (NSCLC) condition card totals 8 registered trials; most-linked intervention Circulogene liquid biopsy testing; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.